Guide-hf study data show abbott's cardiomems™ device can improve care for more patients with heart failure

Abbott park, ill., aug. 27, 2021 /prnewswire/ -- abbott (nyse: abt) today announced results of the landmark guide-hf clinical trial, a 1,000 patient randomized study designed to assess the benefits of the cardiomems™ hf system in people living with nyha class ii, iii and iv heart failure.
ABT Ratings Summary
ABT Quant Ranking